ReviewDrugs2005
Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 82 citations in OpenAlex.
- A pilot study of rizatriptan and visually-induced motion sickness in migraineurs.International journal of medical sciences · 2009Trial
- Action mechanisms of Onabotulinum toxin-A: hints for selection of eligible patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Review
- Therapeutic antibodies against CGRP or its receptor.British journal of clinical pharmacology · 2015Review
- Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.CNS drugs · 2014Review
- Effect of the TRPV1 antagonist SB-705498 on the nasal parasympathetic reflex response in the ovalbumin sensitized guinea pig.British journal of pharmacology · 2013Article
- Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis.Neural regeneration research · 2013Article
- Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine.ACS medicinal chemistry letters · 2012Article
- Obesity and chronic daily headache.Current pain and headache reports · 2012Review
- The extracranial vascular theory of migraine: an artificial controversy.Journal of neural transmission (Vienna, Austria : 1996) · 2011Review
- Tension type headache in adolescence and childhood: where are we now?Current pain and headache reports · 2010Review
- Mechanisms involved in the cerebrovascular dilator effects of cortical spreading depression.Progress in neurobiology · 2008Review
- Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.The journal of headache and pain · 2008Review
- Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Calcitonin gene-related peptide (CGRP) is a potent neuromodulator that is expressed in the trigeminovascular system and is released into the cranial circulation in various primary headaches. CGRP is released in migraine, cluster headache and paroxysmal hemicrania. The blockade of its release is associated with the successful treatment of acute migraine and cluster headache. CGRP receptor blockade has recently been shown to be an effective acute anti-migraine strategy and is non-vasoconstricting in terms of the mechanism of action. The prospect of a non-vasoconstricting therapy for acute migraine offers a real opportunity to patients, and perhaps more importantly, provides a therapeutic rationale to reinforce migraine as a neurological disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.